

Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by our proprietary REMaster technology platform, we can now create medicines with the unique ability to alter the way genes are read from the genome, correcting dysregulation or eliminating the gene message altogether. These are innovative therapeutic solutions with the potential to address disease drivers at their origin. Among its major competitors, Remix Therapeutics is ranked in 5th place for NPS while PTC Therapeutics is 1st, and Roche is 2nd.
Remix Therapeutics has a 4.5/5 stars for its overall company culture rated by their employees
